延长释放的皮配方 - - 有临床上有意义的益处吗?
Sandra D Steintorsdottir1,2,3, Marianne Øksnes1,2, Anders P Jørgensen3,4
1Department of Clinical Medicine, University of Bergen, Bergen N-5020, Norway.
The Journal of clinical endocrinology and metabolism
|December 10, 2024
概括
延长释放皮松 (ER-HC) 可能改善上腺功能不全患者的生活质量. 本综述检查了ER-HC是否比传统治疗提供了显著的好处.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 上腺功能不全的患者经历了生活质量的降低,尽管皮质类固醇治疗.
- 传统的皮的半衰期很短,需要频繁的剂量.
- 延长释放皮质 (ER-HC) 配方允许使用较少的剂量.
研究的目的:
- 审查比较ER-HC与常规皮激素用于上腺功能不全的研究.
- 评估ER-HC配方的安全性和临床益处.
- 调查ER-HC报告影响背后的原因.
主要方法:
- 对皮的配方进行比较研究的系统审查.
- 对药理动力学和药理动力学数据的分析.
- 评估临床结果,包括生活质量,代谢参数和安全性.
主要成果:
- 研究表明,ER-HC可能导致体重,血压和葡萄糖水平降低.
- 随着ER-HC的使用,人们经常报告生活质量的改善.
- 精确的机制 (皮质醇暴露与药理动力学) 需要进一步阐明.
结论:
- ER-HC配方为上腺功能不全提供了潜在的改善治疗选择.
- 需要进一步的研究来确认长期的安全性和临床意义.
- 了解药理动力学差异是优化ER-HC治疗的关键.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
218
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
218
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Drug Delivery: Miscellaneous Routes
320
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
320
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
COPD: Management Using Bronchodilators and Corticosteroids
178
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
178
Antiasthma Drugs: Leukotriene Modifiers
243
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
243


